Reversible mhc multimer staining for functional purification of antigen-specific t cells
AssigneeIba GmbH
InventorsDirk H. Busch, Hermann Wagner
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new method for reversible staining and functional isolation or characterization of cells, e.g. antigen-specific T cells. With this technique, the original functional status of cells can be substantially maintained after their identification and purification. Thus, this new method is of broad benefit for basic research and clinical applications.
Claims29
A method for reversible staining of cells comprising the steps:
- (a) providing a sample comprising a cell having a receptor molecule,
- (b) contacting said cell with
- (i) at least one component specifically binding to said receptor wherein said at least one component is conjugated to at least one first partner of a binding complex, wherein the component and the receptor exhibit a low-affinity interaction;
- (ii) at least one further partner of said binding complex having at least two binding sites for said first partner and
- (iii) a detectable label bound to or capable of binding to (i) and/or (ii), wherein the first partner(s) and the further partner(s) of the binding complex are capable of forming a reversible bond and wherein an aggregate comprising at least two components (i), at least one component (ii) and at least one component (iii) is bound via the receptor molecule to said cell, wherein said cell is stained,
- (c) optionally separating said stained cell from other components of said sample and
- (d) optionally removing said staining from said cell by disrupting the reversible bond.
A method for reversible staining of T cells comprising the steps:
- (a) providing a sample comprising a cell having a T cell receptor (TCR) molecule,
- (b) contacting said T cell with
- (i) at least one TCR binding ligand comprising a TCR binding peptide and an MHC molecule conjugated to at least one first partner of a binding complex, and
- (ii) at least one further partner of a binding complex having at least two binding sites for the first partner of the binding complex and
- (iii) a detectable label bound to or capable of binding to (i) and/or (ii), wherein the first partner(s) and the further partner(s) of the binding complex are capable of forming a reversible bond and wherein an aggregate comprising at least two TCR binding ligands (i), at least one component (ii) and at least one component (iii) is bound via the TCR molecule to said T cell, wherein said T cell is stained,
- (c) optionally separating said stained T cell from other components of said sample, and
- (d) optionally removing said staining from the T cell by disrupting the reversible bond.
Reagent kit for reversible staining of cells comprising
- (i) at least one component specifically binding to a receptor molecule on a cell wherein said at least one component is conjugated to at least one first partner of a binding complex, wherein the component and the receptor exhibit a low-affinity interaction,
- (ii) at least one further partner of said complex having at least two binding sites for said first partner, and
- (iii) a detectable lable bound or capable of binding to (i) and/or (ii), wherein the first partner(s) and the second partner(s) of the binding complex are capable of forming a reversible bond.
Reagent kit for reversible staining of T cells comprising
- (i) at least one TCR binding ligand comprising at least an MHC molecule conjugated to at least one first partner of a binding complex,
- (ii) at least one further partner of a binding complex having at least two binding sites for the first partner of the binding complex and
- (iii) a detectable label bound or capable of binding to (i) and/or (ii), wherein the first partner(s) and the further partner(s) of the binding complex are capable of forming a high affinity reversible bond.
Substantially pure target cell population, wherein said cell population is defined by the presence of a specific common receptor and which has been purified from a heterogeneous cell population using an affinity reagent binding to said common receptor, wherein said affinity reagent has been substantially completely removed from said receptor.
Substantially pure antigen-specific T cell population having a functional status which is substantially unaltered by the purification.
A fusion polypeptide comprising (a) at least one peptide domain which is a first partner of a binding complex, which is capable of forming a reversible bond with at least one further partner of the binding complex and (b) a ligand domain which binds specifically but with low affinity to a receptor on a cell surface.
A fusion polypeptide comprising (a) at least one streptavidin-binding peptide and (b) an MHC molecule.
Dependencies are inferred from the claim text.